Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05548777 · ClinicalTrials.gov registry record
Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 5,480
- Enrollment target
NCT05548777: Completed study, sponsored by AstraZeneca.
NCT05548777 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 5,480 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05548777 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 5,480 participants
- Enrollment target
Study Summary
This is an observational study based on data collected via an audit of electronic medical charts. The study population will include adult US patients treated with andexanet alfa or 4F-PCC during a hospitalization for an anticoagulation-related major bleed, and their characteristics, treatments and outcomes will be described.
Primary Outcome
In-hospital mortality
Interventions
- DRUG Andexanet alfa
- DRUG 4F-PCC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,480 participants |
| Start Date | 2022-09-15 |
| Est. Completion | 2022-12-20 |
What the finished NCT05548777 record still lists
NCT05548777 is an observational study that tracks outcomes without assigning an intervention. Its 5,480 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Andexanet alfa is the first listed.
NCT05548777 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05548777 about?
NCT05548777 is a clinical study titled "Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed". This is an observational study based on data collected via an audit of electronic medical charts. The study population will include adult US patients treated with andexanet alfa or 4F-PCC during a hospitalization for an anticoagulation-related major bleed, and their characteristics, treatments and o...
What is the current status of trial NCT05548777?
This trial is currently completed. The enrollment target is 5,480 participants. The study started on 2022-09-15. Estimated completion is 2022-12-20.
What interventions are being tested in trial NCT05548777?
The interventions under investigation include: Andexanet alfa (DRUG), 4F-PCC (DRUG).
Who is sponsoring clinical trial NCT05548777?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04295486 · 5,478 participants · Phase 2
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
- NCT05952557 · 5,500 participants · Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
- NCT06084234 · 5,500 participants · Phase 4
National Liver Cancer Screening Trial
- NCT07146568 · 5,515 participants · NA
Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hospital
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI